Skip to main content
. 2021 Nov 28;71(7):1747–1756. doi: 10.1007/s00262-021-03108-x

Table 3.

Tumour responses based on RECIST v1.1 criteria according to the baseline tumour size for each group

Overall, n (%) BTS ≤ 86 mm,
n (%)
BTS > 86 mm,
n (%)
p-value
Pembrolizumab group N = 96 N = 50 N = 46
 ORR 57 (59.4) 31 (62.0) 26 (56.5) 0.74
 DCR 72 (75.0) 41 (82.0) 31 (67.4) 0.16
Chemotherapy group N = 92 N = 47 N = 45
 ORR 15 (16.3) 8 (17.0) 7 (15.6) 1
 DCR 55 (59.8) 31 (66.0) 24 (53.3) 0.31